I messed up the Q4 commercial revenue that's required to achieve the $52M midpoint, it should be $16.3M. I had included some BARDA revenue to get $16.05M.
In any case, it's great to see those milestones being achieved. What's also interesting to think about is that since FDA approval for burns in Sept. 2018, it will have taken around 6 years to reach $100M/yr (2024), but it could take less than 2 years to reach $200M/yr (2025-2026?) as market penetration in burns and FTSD increases, and new revenue streams are added.
From what I've heard, another possible catalyst which hasn't been mentioned yet and will increase usage/revenue in the U.S. is there could be favourable reimbursement revisions assigned to RECELL coming in 2024. I'm guessing it could be related to the inpatient CPT codes; possibly device specific meaning payments will be higher, and simpler to process, than the current epidermal autograft codes.
Ann: AVITA Medical Reports Third Quarter 2023 Results, page-14
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.96 |
Change
0.180(6.47%) |
Mkt cap ! $184.0M | |||
| Open | High | Low | Value | Volume |
| $2.88 | $3.02 | $2.85 | $1.050M | 357.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2051 | $2.97 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.98 | 2891 | 3 |
View Market Depth
| Last trade - 13.51pm 08/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$2.99 |
Change
0.180 ( 8.72 %) |
||||
| Open | High | Low | Volume | ||
| $2.88 | $3.01 | $2.88 | 5153 | ||
| Last updated 14.24pm 08/05/2024 ? | |||||
| AVH (ASX) Chart |